11 completed, 8 terminated, 3 withdrawn, 2 unknown. 25 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 25 | Completed 11, Terminated 8, Withdrawn 3, Unknown 2, Active not recruiting 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Uveitis, Posterior: new trials by email Literature Review of Uveitis, Posterior trials Research Report on Uveitis, Posterior
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis Brepocitinib PO QD, Placebo PO QD - Uveitis, Posterior, Uveitis, Intermediate | Phase 3 | Active not recruiting | Priovant Therapeutics, Inc. | 371 | 2024-09-11 | 2026-01-12 |
| The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Yutiq 0.18 MG Drug Implant, Sham Injection - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Texas Retina Associates | 10 | 2022-10-05 | 2026-10-05 |
| Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases Triamcinolone Acetonide - Central Serous Chorioretinopathy, Irvine-Gass Syndrome | Phase 2 / Phase 3 | Unknown | Benha University | 50 | 2022-04-14 | 2022-04-20 |
| Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert Sham Injector, FAI Insert - Uveitis, Uveitis, Posterior | Phase 3 | Terminated | EyePoint Pharmaceuticals, Inc. | 12 | 2021-10-13 | 2024-12-19 |
| Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis 4 mg CLS-TA Suprachoriodal Injection - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Clearside Biomedical, Inc. | 38 | 2017-04-04 | 2021-06-23 |
| Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis 4mg CLS-TA Suprachoriodal Injection, Sham Procedure - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Clearside Biomedical, Inc. | 160 | 2015-11-17 | 2021-05-28 |
| Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis Sham Injection, FAI Insert - Posterior Uveitis, Intermediate Uveitis | Phase 3 | Completed | EyePoint Pharmaceuticals, Inc. | 153 | 2015-06-02 | 2020-07-21 |
| Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) Gevokizumab - Chronic Uveitis | Phase 3 | Terminated | Institut de Recherches Internationales Servier | 71 | 2014-08-01 | 2020-01-03 |
| An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data Dose 2 gevokizumab - Uveitis | Phase 3 | Terminated | XOMA (US) LLC | 69 | 2014-03-01 | 2015-10-16 |
| Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab - Uveitis | Phase 3 | Terminated | XOMA (US) LLC | 281 | 2012-10-01 | 2016-07-12 |
| Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab - Uveitis | Phase 3 | Terminated | XOMA (US) LLC | 200 | 2012-08-01 | 2016-04-08 |
| Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis Trimethoprim-Sulfamethoxazole - Ocular Toxoplasmosis | Phase 3 | Completed | University of Campinas, Brazil | 141 | 2011-10-01 | 2016-07-12 |
| Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis AIN457 - Uveitis | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2011-03-01 | 2013-12-06 | |
| Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis AIN457, Placebo - Uveitis | Phase 3 | Withdrawn | Novartis | 2010-12-01 | 2020-09-29 | |
| A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis adalimumab - Uveitis | Phase 3 | Completed | AbbVie | 424 | 2010-11-23 | 2021-07-12 |
| Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis AIN457, Placebo - Non-infectious Uveitis | Phase 3 | Terminated | Novartis Pharmaceuticals | 86 | 2010-08-01 | 2016-01-14 |
| Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis AIN457, Placebo - Uveitis | Phase 3 | Terminated | Novartis Pharmaceuticals | 30 | 2010-04-01 | 2015-11-03 |
| Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis AIN457, Placebo - Non-infectious Uveitis | Phase 3 | Terminated | Novartis Pharmaceuticals | 125 | 2010-02-01 | 2015-11-05 |
| Phase III Study in Refractory Behcet's Disease AIN457, Placebo - Behcet Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 118 | 2009-10-01 | 2015-08-31 |
| A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Placebo, LX211 - Uveitis, Posterior, Uveitis, Intermediate | Phase 3 | Completed | Lux Biosciences, Inc. | 218 | 2007-01-01 | 2012-10-11 |
Showing 20 of 25. Sign in to see all of them.
Uveitis, Intermediate (20) · Uveitis (19) · Panuveitis (15) · Uveitis, Anterior (3) · Behcet Syndrome (2) · Chorioretinitis (2) · Cardiovascular Diseases (1) · Central Serous Chorioretinopathy (1) · Dermatitis (1) · Macular Edema (1) · Multifocal Choroiditis (1) · Myocardial Infarction (1) · Pars Planitis (1) · Psoriasis (1)
Eye Diseases (25) · Uveal Diseases (25) · Panuveitis (10) · Uveitis (6) · Choroid Diseases (4) · Choroiditis (4) · Retinal Diseases (4) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Vascular Diseases (3) · Cardiovascular Diseases (2) · Coccidiosis (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2)
secukinumab (6) · Triamcinolone Acetonide (3) · salicylhydroxamic acid (3) · Fluocinolone Acetonide (2) · Adalimumab (1) · Bevacizumab (1) · Bulk Drugs (1) · Cyclosporine (1) · Dexamethasone (1) · Drug Implants (1) · Interferon alpha-2 (1) · Prednisolone (1) · Sulfamethoxazole (1) · Trimethoprim (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1)
Novartis Pharmaceuticals (5) · XOMA (US) LLC (3) · Clearside Biomedical, Inc. (2) · EyePoint Pharmaceuticals, Inc. (2) · Lux Biosciences, Inc. (2) · AbbVie (1) · Allergan (1) · Asociación para Evitar la Ceguera en México (1) · Benha University (1) · Institut de Recherches Internationales Servier (1) · Novartis (1) · Priovant Therapeutics, Inc. (1) · Shahid Beheshti University of Medical Sciences (1) · Texas Retina Associates (1) · University Hospital Tuebingen (1)
United States (16) · Germany (12) · Israel (10) · United Kingdom (10) · India (9) · Spain (9) · France (8) · Austria (6) · Brazil (6) · Canada (6) · Greece (6) · Switzerland (6) · Australia (5) · Italy (5) · Turkey (Türkiye) (5)
Eddy Anglade, M.D. (2) · Ahmed A Abdelshafy, MD (1) · Flavio Leonin Jr., MD (1) · Ina Koetter, MD (1) · LuzElena Concha-Del Rio, MD (1) · Masoud Soheilian, MD (1) · Rodrigo PC Lira, PhD (1) · Thomas Ciulla, MD (1) · Thomas Cuilla, MD, MBA (1) · Veronica Kon-Jara, MD (1)
PMID 23290985, PMID 36399237, PMID 36787524, PMID 12095806, PMID 21220619, PMID 23411886, PMID 23761087, PMID 29370572, PMID 33157077, PMID 34322164, PMID 34741564, PMID 36055922, PMID 38027419
2009 (6)